Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name MDM2 amp
Gene Variant Detail

MDM2 amp (no effect)

Relevant Treatment Approaches MDM2 Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06578624 Phase Ib/II SA53-OS Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06058793 Phase III BI 907828 Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Completed USA | GBR | CAN | BRA | AUS | ARG 1
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Active, not recruiting USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS 2
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Completed USA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS 7
NCT05218499 Phase II BI 907828 Doxorubicin Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Active, not recruiting USA | TUR | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS 5
NCT04776447 Phase II Atezolizumab + Carboplatin + Paclitaxel Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO) Active, not recruiting ESP 0
NCT06025747 Phase I Abemaciclib Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma Recruiting USA 0
NCT07153445 Phase II Atezolizumab + Carboplatin + Paclitaxel Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) (ATHENEA) Recruiting ESP 0
NCT06389799 Phase II Pemigatinib + Retifanlimab A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI) Recruiting SWE | NOR 0
NCT07247786 Phase II Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Fecal microbiota + Paclitaxel Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) (MIGRANT) Not yet recruiting ESP 0
NCT04223596 Phase II Brigatinib Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) Active, not recruiting ESP 0